Press Releases
-
Nov 19, 2019Provides More Than Six Million US Lives Unrestricted Access to Only FDA-Approved 12-Hour Codeine-Based Cold-Cough Syrup...Nov 14, 2019ENGLEWOOD, CO / ACCESSWIRE / November 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today will provide an overview of its business, including the company's operational and financial results for its fiscal first quarter 2020 that ended September 30, 2019. The company will...Nov 11, 2019ENGLEWOOD, CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the hiring of Matthew Phillips as the company's Executive Vice President of Commercial Operations. Mr. Phillips' hiring became effective November 8, 2019 following the rec...Nov 7, 2019ENGLEWOOD, CO / ACCESSWIRE / November 7, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the quarter ended September 30, 2019 on November 14, 2019, at 4:30 p.m. ET. The company will review accomplishment...Nov 4, 2019Asset Purchase Increases Combined Company Annual Revenue to $44M, Including Previously Announced Acquisition of Innovus Pharmaceuticals ...Oct 21, 2019Tuzistra XR Now Covered on Commercial Plans Covering Over 30 Million U.S. Lives...Oct 17, 2019Phase IV, Investigator-Initiated Study is First to Conclusively Show that a Testosterone Replacement Therapy (TRT) Maintains Key Fertility Measures in Men with Low T...Oct 16, 2019Investigator-initiated, Phase IV study results will be presented today at 75th Annual American Society for Reproductive Medicine (ASRM) scientific conference ‘Late Breaking' abstract session...Oct 14, 2019Transaction increases annual revenue to $44M and is expected to accelerate time to breakeven, following recently announced acquisition of Innovus Pharmaceuticals ...Oct 14, 2019Armistice Capital and Altium Capital jointly participated in financing...